ArticleJournal of computer-aided molecular design2025
μOR-ligand: target-aware view-based hybrid feature selection for μ-opioid receptor ligand functional classification.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding active functional class (agonist vs antagonist) at the human μ-opioid receptor (μOR) is critical for drug discovery and safety assessment. While recent machine learning models such as ExtraTrees (ET) and message-passing neural networks (MPNNs) achieved ROC AUC scores of 0.915 ± 0.039 and 0.918 ± 0.044, respectively, it remains unclear how target-conditioned interaction features influence functional class detection and how resampling choices (e.g., SMOTE) impact robustness when evaluated under identical, fixed splits. Therefore, we introduce the μOR-Ligand framework-a target-aware view-based hybrid feature selection to improve performance in identifying whether an active ligand is an agonist or antagonist. To realize μOR-Ligand, three views have been constructed: (1) fingerprint, (2) ligand descriptors, and (3) molecular interaction features, yielding a comprehensive feature space of 114,552 variables (1190 fingerprints, 1618 ligand descriptors, 111,741 interaction descriptors). Feature selection is performed per view to obtain three view-specific subsets; each trains a base learner, and their out-of-fold predictions are fused via a linearly weighted multimodel feature selection stage. In parallel, the three selected feature sets are merged and trained with a stacking model (ensemble feature selection). Finally, μOR-Ligand forms a view-based hybrid feature selection by linearly combining the multimodel and ensemble outputs. Such a target-aware view-based hybrid feature selection for the stacked ensembles framework achieved an improved ROC AUC of 0.930 ± 0.026, supported by a promising significant p-value of 0.046 and a t-statistic of 1.707 (> t-critical=1.663) against the recent model, MPNNs. Also, μOR-Ligand further increased ROC AUC to 0.977 on internal cross-validation, as the highest ROC AUC score. In addition, μOR-Ligand is evaluated under a resampling-controlled μOR evaluation protocol that pairs ± SMOTE on identical, fixed splits. Overall, the study (1) demonstrates that target-aware interaction features, though weak alone, contribute a complementary signal in multimodel fusion, improving performance in functional classification and stability, and (2) establishes a resampling-controlled evaluation protocol for μOR modeling, and (3) identifies correlations between top features and μOR pocket chemistry/residues, and (4) case study to show effectiness on unseen external data, as a real-world application. Overall, the study demonstrates that hybridizing ligand-based and target-conditioned views-via target-aware view-based hybrid feature selection for stacked ensembles-adds complementary signal beyond ligand-only baselines, particularly for functional class (agonist vs antagonist).
Indexed as
Identifiers
41136815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.